Stay updated with breaking news from மார்கோ டைமர்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Byondis B.V.: Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Presentation and webcast to take place at: 07:30 AM EST on January 14 NIJMEGEN, The Netherlands, January 11, 2021 / B3C newswire / Byondis, a clinical-stage biopharmaceutical company today announced that its Chief Executive Officer, Marco Timmers, Ph.D., will present at the J.P. Morgan Healthcare Conference at 07:30 AM EST / 01:30 PM Central European Time (CET) on Thursday, January 14, 2021. A link to the live audio webcast of this presentation will be available on the Events Calendar of www.byondis.com. A replay will also be available on the Byondis website following the presentation.
Driven to improve patients’ lives, Byondis is an independent clinical-stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other biopharmaceutical companies by its proprietary molecular ....
DGAP-News: Byondis B.V.: Byondis Announces Upcoming Presentation at J.P. Morgan Healthcare Conference vom 11.01.2021, 15:00 Uhr Bild: pixabay.com Byondis B.V.: Byondis Announces Upcoming Presentation at J.P. Morgan Healthcare Conference 11.01.2021 / 15:00 Byondis Announces Upcoming Presentation at J.P. Morgan Healthcare Conference Presentation and webcast to take place at: 07:30 AM EST on January 14 Nijmegen, The Netherlands - 11 January 2021 - Byondis, a clinical-stage biopharmaceutical company today announced that its Chief Executive Officer, Marco Timmers, Ph.D., will present at the J.P. Morgan Healthcare Conference at 07:30 AM EST / 01:30 PM Central European Time (CET) on Thursday, January 14, 2021. A link to the live audio webcast of this presentation will be available on the Events Calendar of www.byondis.com. A replay will also be available on the Byondis website following the presentation. ....